Codexis, Inc.

NASDAQ:CDXS

Biotechnology

Healthcare
$1.15 +0.60%

+$0.02 today

Market cap
$126.04M
Beta
2.48
P/E (TTM)
-7.1
EPS (TTM)
-$0.35
52W Low $0.96High $3.87

Volume 1.47M

Average 1.15M

CDXS Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Codexis, Inc.NASDAQ: CDXS

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables declines year over year

Q1 FY2026 accounts payables of $312K fell 84.9% year over year, ahead of the -297.9% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables amounted to 1.8% of revenue in FY2025, down 2.5 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -84.9% holds above the trailing-twelve-month pace of -297.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$312K+139.3% QoQ
Last fiscal yearDec 2025
-$1.29M-49.9% YoY
LTMMar 2026
-$3.04M-297.9% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-84.9%——
1 year-49.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(1.29M) USD
Year-over-year change
+49.9%

Accounts Payables vs competitors

How CDXS compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -297.9% is the lowest of 9, against a peer median of -21.0%.
  • Accounts payables amounts to 3.9% of revenue for CDXS, versus a peer median of 7.3%.
CDXS Competitors
Accounts Payables for CDXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVVDInvivyd, Inc.LTM Mar 2026$6.72M USD-188.7%—12.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$3.51M USD+170.1%-40.6%10.2%
CDXSCodexis, Inc.LTM Mar 2026$3.04M USD-297.9%—3.9%
TARAProtara Therapeutics, Inc.LTM Mar 2026$1.72M USD+28.5%——
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$662K USD-192.7%—20.9%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$337K USD-70.4%+107.3%17.3%
OABIOmniAb, Inc.LTM Mar 2026$215K USD+111.0%—0.7%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$133K USD-95.3%—4.5%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$92K USD+109.7%-48.0%0.3%
IPHAInnate Pharma S.A.FY2025€0 EUR——0.0%
Peer median (excluding CDXS) —-21.0%-40.6%7.3%

Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.28M)(33.59M)(76.24M)(65.28M)(43.97M)
Depreciation & Amortization5.95M10.25M9.92M4.95M5.25M
Deferred Income Tax(2.89M)0000
Stock-Based Compensation11.59M14.53M9.97M13.09M9.62M
Change in Working Capital(7.62M)21.57M(18.22M)(12.02M)6.42M
Accounts Receivables(15.57M)(3.23M)20.25M1.25M8.51M
Inventory(196K)(869K)(656K)886K(19K)
Accounts Payables268K207K2.29M(2.57M)(1.29M)
Other Working Capital7.88M25.46M(40.1M)(11.59M)(784K)
Other Non-Cash Items(19K)(1.48M)21.93M9.85M3.31M
Operating Cash Flow(14.27M)11.28M(52.64M)(49.41M)(19.38M)
Capital Expenditures(13.83M)(8.31M)(4.42M)(4.31M)(4.47M)
Acquisitions (Net)36K29K751K87K5K
Purchases of Investments(7.63M)(5.3M)(1.19M)(90.24M)(57.16M)
Sales of Investments(36K)(29K)440K37.47M85.13M
Other Investing Activities36K29K(440K)00
Investing Cash Flow(21.42M)(13.58M)(4.86M)(56.98M)23.5M
Debt Repayment00029.52M9.89M
Common Stock Issued4.97M913K8.65M31.32M18.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.21M)(1.49M)(485K)(318K)0
Financing Cash Flow3.77M(575K)8.17M60.52M27.93M
Effect of Forex Changes00000
Net Change in Cash(31.92M)(2.87M)(49.33M)(45.87M)32.05M
Free Cash Flow(28.1M)2.98M(57.06M)(53.72M)(23.85M)

Codexis, Inc.

NASDAQ:CDXS

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.